Cannabinoids: A New Group of Agonists of PPARs
Cannabinoids have been used medicinally and recreationally for thousands of years and their effects were proposed to occur mainly via activation of the G-protein-coupled receptor CB1/CB2 (cannabinoid receptor 1/2). Discovery of potent synthetic analogs of the natural cannabinoids as clinically usefu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2007-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2007/23513 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cannabinoids have been used medicinally and recreationally for thousands of years
and their effects were proposed to occur mainly via activation of the G-protein-coupled
receptor CB1/CB2 (cannabinoid receptor 1/2). Discovery of potent synthetic
analogs of the natural cannabinoids as clinically useful drugs is the sustained aim of
cannabinoid research. This demands that these new compounds be free of the
psychotropic effects that connected with the recreational use of cannabinoids. In
preclinical studies cannabinoids displayed many of the characteristics of nonsteroidal
anti-inflammatory drugs (NSAIDs) and it seems to be free of unwanted side effects.
An increasing number of therapeutic actions of cannabinoid are being reported that do
not appear to be mediated by either CB1 or CB2, and recently nuclear receptor
superfamily PPARs (peroxisome-proliferator-activated receptors) have been
suggested as the target of certain cannabinoids. This review summarizes the evidence
for cannabinoid activation on PPARs and possible associated remedial potentials. |
|---|---|
| ISSN: | 1687-4757 1687-4765 |